作者:Ferdinando Fiorino、Martin Eiden、Armin Giese、Beatrice Severino、Antonella Esposito、Martin H. Groschup、Elisa Perissutti、Elisa Magli、Giuseppina Maria Incisivo、Antonio Ciano、Francesco Frecentese、Hans A. Kretzschmar、Jens Wagner、Vincenzo Santagada、Giuseppe Caliendo
DOI:10.1016/j.bmc.2012.06.026
日期:2012.8
A new set of 5-(2-(pyrrolidin-1-yl)acetamido)-N-butyl-2-(substituted) benzamide and 5-(2-(piperidin-1-yl)acetamido)-N-butyl-2-(substituted) benzamide derivatives were synthesized in which as structural features the 2-(1-pyrrolidinyl)- or 2-(1-piperidyl) acetylamino group or a diphenylether moiety are associated to a benzamide scaffold. Their binding affinity for human PrPC and inhibition of its conversion into PrPSc were determined in vitro; moreover, the antiprion activity was assayed by inhibition of PrPSc accumulation in scrapie-infected mouse neuroblastoma cells (ScN2a) and scrapie mouse brain (SMB) cells. The results clearly indicate the benzamide derivatives as attractive lead compounds for the development of potential therapeutic agents against prion disease. (C) 2012 Elsevier Ltd. All rights reserved.